Inappropriate Use Of Amfepramone Prompts EU Withdrawal Of Weight-Loss Drug
EMA Issues Warning Over Xalkori And Oular Toxicity In Pediatric Patients
The European Medicines Agency’s pharmacovigilance committee has recommended removing all amfepramone medicines from the EU market as they continue to be used outside the current risk minimization measures.
You may also be interested in...
Markus Ambrosius examines the implications for pharmaceutical companies of the recent court ruling.
Court rejects European ban
The EU’s conditional approval of four COVID-19 vaccines and its decision to extend the use of Pfizer/BioNTech’s Comirnaty to a younger age group were challenged in the court last year but the cases were declared inadmissible.